Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer

Urologia Internationalis

Volumn 72, Issue 2, 2004, Pages 91-98

  Sciarra, Alessandro ^a,b   Cardi, Antonio ^a   Di Silverio, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; NILUTAMIDE;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DATA BASE; DIARRHEA; GYNECOMASTIA; HUMAN; INTERMETHOD COMPARISON; LIBIDO DISORDER; LIVER DYSFUNCTION; MEDLINE; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANILIDES; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; FLUTAMIDE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 1242329061     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075960     Document Type: Review

References (41)

1. Iversen P: Endocrine therapy: Goals and limitations; in Schroder FH (ed): Recent Advances in Prostate Cancer and BPH. London, 1997, pp 147-158.
2. Boccon-Gibod L, Fournier G, Botter P: Flutamide versus orchiectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32:391-396.
3. Neumann F, Jacobi GH: Antiandrogens in tumor therapy. Clin Oncol 1982;1:41-64.
4. Eisemberger M, Crawford ED, McLeod D, Loehrer P: A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. 33rd Ann Meet American Society of Clinical Oncology, 1997, A1311.
5. van Andel G, Kurth KH: Quality of life in prostate cancer: Preliminary results of two studies in patients with extensive disease. 4th Int Symp Recent Advances in Urological Cancer, Paris, 1994, pp 191-203.
6. Iversen P: Quality of life issues relating to endocrine treatment options. Eur Urol 1999; 36(suppl 2):20-26.
7. Daniel HW: Ospeoporosis after orchoectomy for prostate cancer. J Urol 1997;157:439-444.
8. Townsend MF, Sanders WH, Northwat RO, Graham SD: Bone fracture associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 1997;79:545-550.
9. Tyrrel CJ, Kaisary AV, Iversen P, Andersson JB, Baert L: A randomised comparison of Casodex 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-456.
10. Iversen P, Tyrrel CJ, Kaisary AV, Anderson JB, Baert L: Casodex 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicenter randomised trials at a median follow-up of 4 years. Urology 1998;51:389-396.
11. Cleary PD, Morrissey G, Oster G: Health-related quality of life in patients with advanced prostate cancer: A multinational perspective. Qual Life Res 1995;4:207-220.
12. Calero JA, Diaz-Curiel M: Bicalutamide treatment does not produce bone effects in male Wistar rats. J Bone Min Res 1999;14(suppl 1):S220(abstr F034).
13. Di SilverioF, Serio M: Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: A multicentre italian study. Eur Urol 1990;18:54-61.
14. Schroder FH, Whelan P, Kurh KH, de Pauw M: Antiandrogens as monotherapy for metastatic prostate cancer: A preliminary report on EORTC protocol 30892; in Schroder FH (ed): Recent Advances in Prostate Cancer and BPH. London, Parthenon Publishing, 1997, pp 141-146.
15. Schroder FH, Collette L, de Reijke TM, Whelan P: Prostate cancer treated by antiandrogen: is sexual function preserved? Br J Cancer 2000;82:283-290.
16. Barradell LB, Faulds D: Cyproterone: A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994;5:59-80.
17. de Voogt HJ, Smith PH: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate, and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from EORTC trials 30761 and 30762. J Urol 1986;135:303-307.
18. Moffat LEF: Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18(suppl 3):26-27.
19. Lund F, Rasmussen F: Flutamide versus stilbestrol in the management of advanced prostatic cancer: A controlled prospective study. Br J Urol 1988;61:140-142.
20. Wysowski DK, Fourcroy JL: Flutamide hepatotoxicity. J Urol 1996;155:209-212.
21. Decensi AU, Boccardo F: Monotherapy with nilutamide, a pure antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377-381.
22. Iversen P: Antiandrogen monotherapy; in Kurth KH (ed): Renal, Bladder and Prostate Cancer. Progress Controversies in Oncological Urology. London, Parthenon Publishing, 1999: pp 183-190.
23. Ostri P, Bonnesen T, Nilsson T: Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: A prospective randomised trial. Urol Int 1991;46:167-171.
24. Thorpe SC: A prospective randomised study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostate carcinoma. Eur Urol 1996;29:47-54.
25. Pavone Macaluso M, de Voogt HJ, Viggiano G, Barasolo E: Comparison of of advanced prostate cancer: Final analysis of a randomized phase III trial of the EORTC. J Urol 1986;136:624-631.
26. Boccon-Gibod L, Fournier G, Battet P, Mallo C: Flutamide versus orchidectomy in patients with metastatic prostate carcinoma. J Urol 1992; 147:417A.
27. Tyrrell CJ: Casodex: A pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer. Prostate 1992;(suppl 4): 97-104.
28. Iversen P: Update of monotherapy trials with the new antiandrogen Casodex. Eur Urol 1994;26(suppl 1):5-9.
29. Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(suppl 1A):38-43.
30. Fourcade RO: An open multicentre study to compare the effect and safety of Casodex 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 1998;33(suppl 1):88A.
31. Boccardo R, Rubagotti A, Barichello M: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an italian prostate cancer project study. J Clin Oncol 1999;17:2027-2038.
32. Iversen P, Tyrrel CJ, Kaisay AV, Anderson JP: Bicalutamide 150 mg monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years follow-up. J Urol 2000;164:1579-1582.
33. Wirth M, Froehner M: A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999; 36(suppl 2):14-19.
34. Wirth M, Frohmuller H, Marz F, Bolten M, Theib M: Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery: Interim analysis of treatment effect and prognostic factors. Br J Urol 1997;80(suppl 2):263 (abstr 1033).
35. See WA, McLeod D, Iversen P, Wirth M: The bicalutamide early prostate cancer program: demography. Urol Oncol 2001;6:43-47.
36. Wirth M, Tyrrel C, Wallace M, Delaere KP: bicalutamide 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urol 2001;58:146-151.
37. Iversen P, Wirth M, See W, McLeod D: Is the efficacy of hormonal therapy affected by limph node status? New data from the bicalutamide EPC program. J Urol 2002;167:1355A.
38. Wirth M, McLeod D, Iversen P, See W: Efficacy of bicalutamide in early non metastatic prostate cancer by initial desease state and grade. J Urol 2002;167:1367A.
39. Tan A, Tuckey J, Rice M: Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer. Eur Urol 2001;40:130-134.
40. Byar DP: The Veterans Administration Cooperative Urological Research Group studies of cancer of the prostate. Cancer 1973;32:1126-1130.
41. Newling D: Advanced prostate cancer: Immediate or deferred hormone therapy? Eur Urol 2001;39(suppl 1):15-21.